•Apogee Therapeutics announced a $1.3 billion strategic financing collaboration with Blackstone Life Sciences to advance Phase 3 development and commercialization of Zumilokibart.
•The Phase 2 APEX trial of Zumilokibart in moderate-to-severe atopic dermatitis met all primary and secondary endpoints, with Phase 3 trials planned for 2H 2026.